Oramed Pharmaceuticals
ORMP
15 hedge funds and large institutions have $1.91M invested in Oramed Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 5 closing their positions.
312% more call options, than puts
Call options by funds: $507K | Put options by funds: $123K
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
12% less funds holding
Funds holding: 17 → 15 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
44% less capital invested
Capital invested by funds: $3.37M → $1.91M (-$1.47M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.45M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$36.8K |
| 3 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$18.6K |
| 4 |
Morgan Stanley
New York
|
+$5.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$4.86K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$2.61M |
| 2 |
TSS
Two Sigma Securities
New York
|
-$75K |
| 3 |
GIM
Greylin Investment Management
Orange,
Virginia
|
-$33.5K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$14.2K |
| 5 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$11K |
ORMP Hedge Fund Activity: Q2 2015 in Review
15 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q2 2015, worth a combined $1.91M — down 44% from $3.37M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ORMP and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.45M. The largest seller was AWM Investment Company, exiting entirely with an estimated $2.61M sold.
- 15 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q2 2015, down from 17 in Q1 2015.
- Funds reported $1.91M of Oramed Pharmaceuticals stock for Q2 2015, down 44% quarter-over-quarter.
- 3 funds opened new Oramed Pharmaceuticals positions in Q2 2015 and 5 closed out, a net change of -2 holders.
- The largest Oramed Pharmaceuticals buyer in Q2 2015 was Sabby Management, an estimated $1.45M added.
- The largest Oramed Pharmaceuticals seller in Q2 2015 was AWM Investment Company, an estimated $2.61M sold.
Based on aggregated 13F filings for Q2 2015.